suvorexant (belsomra) Report issue

Small molecule Approved FDA First in Class
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R. It has been approved for the treatment of insomnia. The mechanism by which suvorexant exerts its therapeutic effect in insomnia is presumed to be through antagonism of orexin receptors. The orexin neuropeptide signaling system is a central promoter of wakefulness. Blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive.   NCATS

Chemistry

  • SMILES: C[C@@H]1CCN(CCN1C(=O)C2=CC(C)=CC=C2N3N=CC=N3)C4=NC5=C(O4)C=CC(Cl)=C5
  • InChIKey: JYTNQNCOQXFQPK-MRXNPFEDSA-N
  • Mol. Mass: 450.921
  • ALogP: 4.11
  • ChEMBL Molecule:
    suvorexant  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$8.4650 - $12.2906
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone | [(7r)-4-(5-chlor-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl]methanon | [(7r)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl]methanone | [(7r)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-méthyl-1,4-diazépan-1-yl][5-méthyl-2-(2h-1,2,3-triazol-2-yl)phényl]méthanone | [(7r)-4-(5-chlorobenzoxazol-2-yl)-7-methylhexahydro-1h-1,4-diazepin-1-yl][5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl]methanone | belsomra | methanone, ((7r)-4-(5-chloro-2-benzoxazolyl)hexahydro-7-methyl-1h-1,4-diazepin-1-yl)(5-methyl-2-(2h-1,2,3-triazol-2-yl)phenyl)- | mk4305 | mk 4305 | mk-4305 | suvorexant

Organizations (48)

Research & Development (48)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (48)

Approved Indications (1)


 

Sleep Initiation and Maintenance Disorders

Experimental Indications - Clinical Trial Phases 1-4 (48)


 

Alcohol-Induced Disorders (Phase 2)

Alcoholism (Phase 2)

Alzheimer Disease (Phase 3)

Analgesics, Opioid (Phase 2)

Anxiety (Phase 2)

Autism Spectrum Disorder (Phase 2)

Autistic Disorder (Phase 2)

Bipolar Disorder (Phase 4)

Breast Neoplasms (Phase 4)

Cocaine-Related Disorders (Phase 2)

Cognitive Aging (Phase 2)

Cortisone (Phase 2/Phase 3)

Craving (Phase 2/Phase 3)

Delirium (Phase 3)

Depression (Phase 4)

Depressive Disorder (Phase 4)

Depressive Disorder, Major (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Drugs, Investigational (Phase 2)

Fatigue (Phase 4)

Fibromyalgia (Phase 4)

Healthy Volunteers (Phase 1)

Hepatic Insufficiency (Phase 1)

Hypertension (Phase 4)

Inflammation (Phase 4)

Menopause (Phase 4)

Methamphetamine (Phase 2)

Multiple Sclerosis (Phase 4)

Opioid-Related Disorders (Phase 2)

Panic Disorder (Early Phase 1)

Performance-Enhancing Substances (Early Phase 1)

Placebos (Phase 2)

Postoperative Complications (Phase 4)

Restless Legs Syndrome (Phase 4)

Sleep (Phase 2)

Sleep Apnea Syndromes (Phase 1)

Sleep Deprivation (Phase 4)

Sleep Disorders, Circadian Rhythm (Phase 4)

Sleep Disorders, Intrinsic (Phase 2/Phase 3)

Sleep Initiation and Maintenance Disorders ()

Sleep Wake Disorders (Phase 4)

Smoking Cessation (Phase 2)

Stress Disorders, Post-Traumatic (Phase 4)

Substance Abuse, Oral (Phase 1)

Substance-Related Disorders (Phase 2)

Therapeutics (Phase 4)

Tobacco Use Disorder (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 60
  • # of Trial Organizations: 48

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue